

1.0.7 DOC EIA

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NICE guidelines

Equality impact assessment

Advanced breast cancer (standing committee update)

The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

1.0 Scope: before consultation

1.1 Have any potential equality issues been identified during the development of the draft scope, before consultation, and, if so, what are they?

Not applicable (Clinical Guideline Updates do not include scoping phase).

1.2 What is the preliminary view on the extent to which these potential equality issues need addressing by the Committee? For example, if population groups, treatments or settings are excluded from the scope, are these exclusions justified – that is, are the reasons legitimate and the exclusion proportionate?

Not applicable (Clinical Guideline Updates do not include scoping phase).

1.0.7 DOC EIA

2.0 Scope: after consultation

2.1 Have any potential equality issues been identified during consultation, and, if so, what are they?

Not applicable (Clinical Guideline Updates do not include scoping phase).

2.2 Have any changes to the scope been made as a result of consultation to highlight potential equality issues?

Not applicable (Clinical Guideline Updates do not include scoping phase).

2.3 Is the primary focus of the guideline a population with a specific disability-related communication need?

If so, is an alternative version of the 'Information for the Public' document recommended?

If so, which alternative version is recommended?

The alternative versions available are:

- large font or audio versions for a population with sight loss;
- British Sign Language videos for a population who are deaf from birth;
- 'Easy read' versions for people with learning disabilities or cognitive impairment.

No.

1.0.7 DOC EIA

3.0 Guideline development: before consultation

3.1 Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

Not applicable (Clinical Guideline Updates do not include scoping phase).

3.2 Have any **other** potential equality issues (in addition to those identified during the scoping process) been identified, and, if so, how has the Committee addressed them?

The committee discussed any potential equality issues in particular issues relating to the protected characteristics under the Equalities Act. However no equality issues relating to the review question under consideration were identified.

3.3 Were the Committee's considerations of equality issues described in the consultation document, and, if so, where?

Yes - these are contained in the Linking Evidence To Recommendations table in the guideline. Relevant subgroups have also been specified in the review protocol.

3.4 Do the preliminary recommendations make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

1.0.7 DOC EIA

3.4 Do the preliminary recommendations make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3.5 Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

3.6 Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 3.1, 3.2 or 3.3, or otherwise fulfil NICE's obligation to advance equality?

No equality issues relating to the updated review questions were identified.

Completed by Developer Nicole Elliott, CGUT Guideline Lead

Date 01 December 2016

Approved by NICE quality assurance lead Christine Carson, NICE Guideline Lead

Date 10 May 2017